Resources
About Us
Home Report
Store
Indonesia IVD Market
Indonesia IVD Market by Product (Kits, Instruments, Software), Technology (Immunoassay, Hematology, Coagulation, Diabetes, Molecular), Application (Infectious Diseases, Cardiology, Oncology), and End User (Hospital, Diagnostic Lab, Home Care) - Forecast to 2029
Report ID:MRHC - 104668 Pages: 160 Sep-2022 Formats*: PDF Category: Healthcare Delivery: 2 to 4 HoursThe Indonesia IVD Market is expected to reach $1.11 billion by 2029, at a CAGR of 10.6% from 2022 to 2029. The growth of this market is driven by the high prevalence of infectious and chronic diseases and the growing awareness regarding the importance of early disease diagnosis. Furthermore, Indonesia’s rising health spending and the growing scope for foreign investments are expected to create significant growth opportunities for the players operating in this market. However, the shortage of healthcare professionals and the high prices of advanced IVD products are major challenges for market growth.
Impact of COVID-19 on the Indonesia IVD Market
The COVID-19 pandemic negatively impacted the Indonesia IVD market in the initial phase of the pandemic, as the Government imposed lockdowns and various restrictions to curb the spread of the virus. Domestic and international air & sea travel was banned. Restrictions were placed on public events, and schools and other educational institutions were closed temporarily. Consequently, the country’s GDP declined by 0.7% in Q1 2021 compared to Q1 2020 (Source: International Monetary Fund). The shrinking GDP negatively impacted businesses and industries, including healthcare. Moreover, the lockdowns and restrictions imposed during the initial stages of the pandemic disrupted supply chains, negatively impacting the Indonesia IVD market. Non-priority diagnostic procedures had to be postponed or canceled due to the overburdening of hospitals, clinics, and diagnostic laboratories, temporarily hindering the growth of Indonesia’s IVD market.
However, in the later stages of the pandemic, the Government of Indonesia took initiatives to boost COVID-19 testing in the country. The government distributed PCR machines, PCR kits, and other consumables. Furthermore, the Government-designated laboratories for COVID-19 testing increased. The number of laboratories designated to test for COVID-19 increased to 742 by May 2021, compared to 466 laboratories in November 2020. These initiatives boosted the growth of the IVD market in Indonesia.
Click here to: Get Free Sample Copy of this report
Indonesia’s Rising Healthcare Spending to Offer Significant Growth Opportunities for Players Operating in the Indonesia IVD Market
Indonesia started rapidly increasing its healthcare spending after the outbreak of the COVID-19 pandemic, which was a necessary measure to effectively vaccinate and manage the country’s large population. Indonesia’s annual health spending has increased from $8.07 billion (Rp 113.6 trillion) in 2019 to $17.62 billion (Rp 255.3 trillion) in 2022 (Source: Indonesia’s Finance Ministry). This significant increase in health spending was mainly for diagnostics, testing & tracing, health equipment, COVID-19 hospital treatment, and financial incentives for healthcare workers. Indonesia’s increasing health spending is aimed at improving the country’s healthcare infrastructure and acquiring advanced In vitro diagnostic technologies to improve testing capabilities. Thus, Indonesia’s rising health spending is expected to create significant growth opportunities for the players operating in the IVD market in Indonesia.
Key Findings of the Indonesia IVD Market Study:
In 2022, the molecular diagnostics segment is slated to register the highest CAGR during the forecast period
The segment's growth can be attributed to the initiatives by the Government, private players, and institutions to support the development of molecular diagnostics and the constant innovations and advancements in molecular technologies.
The reagent, assays, and kits segment is projected to register the highest CAGR during the forecast period
The rising adoption of point-of-care tests, the rising prevalence of chronic & infectious diseases, and the increasing launches of disease-specific kits are the key factors contributing to the demand for consumables. Furthermore, the COVID-19 pandemic significantly boosted the demand for IVD reagents, assays, and kits in the country.
The oncology segment is projected to register the fastest growth during the forecast period
The growth of this segment is driven by the increasing incidence rate of cancer in the country. According to International Agency for Research on Cancer, in 2020, 396,914 new cancer cases were reported in Indonesia, which is estimated to increase to 522,246 by 2030.
The home care/self-testing segment is slated to register the highest CAGR during the forecast period
The rising availability of home test kits for several diseases, the rising aging population, the rising awareness among patients about self-testing kits, and the ongoing transition from hospital to home health care to curtail the rising costs are the factors driving the growth of this segment. The emergence of accessible and affordable self-testing kits and the high prevalence of diseases that can be self-monitored such as diabetes & COVID-19, are expected to increase the adoption of home care/self-testing kits during the forecast period.
Key Players
The report includes a competitive landscape based on an extensive assessment of the product portfolios and geographic presence of key players and the key growth strategies adopted by major market players between last three years. The key players profiled in the Indonesia IVD market study are F. Hoffman-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Abbott Laboratories (U.S.), Danaher Corporation (U.S.), Becton, Dickinson and Company (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Qiagen N.V. (Netherlands), Siemens Healthineers AG (Germany), and Sysmex Corporation (Japan).
Scope of the Report:
Indonesia In Vitro Diagnostics Market, by Product
- Reagents, Assays, and Kits
- Analyzers/Instruments
- Software & Services
Indonesia In Vitro Diagnostics Market, by Technology
- Immunoassay
- Clinical Chemistry
- Molecular Diagnostics
- Hematology
- Coagulation & Hemostasis
- Electrolyte Analysis
- Diabetes/Glucose Monitoring
- Urinalysis
- Other Technologies
Note: Other technologies comprise clinical microbiology, hybridization, and loop-mediated amplification.
Indonesia In Vitro Diagnostics Market, by Application
- Infectious Diseases
- Diabetes
- Oncology
- Cardiology
- Other Applications
Note: Other applications comprise endocrinology, toxicology, nephrology, gastroenterology, neonatal, genetic, and neurological disorders.
Indonesia In Vitro Diagnostics Market, by End User
- Hospital Laboratories
- Clinical Laboratories
- Large/Reference Laboratories
- Medium-sized Laboratories
- Small-sized Laboratories
- Home Care/Self Testing
- Other End Users
Note: Other end users comprise nursing homes, academic & research institutes, ambulatory care centers, and transfusion laboratories.
Key questions answered in the report:
The study covers the market sizes & forecasts of the Indonesia IVD market based on product, technology, application, and end user. This report also involves the value analysis of various segments and subsegments of the Indonesia IVD Market.
The Indonesia IVD Market is projected to reach $1.11 billion by 2029, at a CAGR of 10.6% during the forecast period.
In 2022, the reagents, assays, and kits segment is expected to account for the largest share of the Indonesia IVD Market. This segment is also slated to register the highest CAGR during the forecast period.
The molecular diagnostics segment is projected to create more traction due to the technological advancements in molecular diagnostics and the Government’s initiatives to establish molecular diagnostic centers in the country.
The growth of this market is driven by the high prevalence of infectious and chronic diseases and the growing awareness regarding the importance of early disease diagnosis. In addition, Indonesia’s rising health spending and the growing scope for foreign investments are expected to provide significant growth opportunities for players operating in the Indonesia IVD Market.
The key players operating in the Indonesia IVD market are F. Hoffman-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Abbott Laboratories (U.S.), Danaher Corporation (U.S.), Becton, Dickinson and Company (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Qiagen N.V. (Netherlands), Siemens Healthineers AG (Germany), and Sysmex Corporation (Japan).
1. Introduction
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Process
2.2. Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research
2.3. Market Assessment
2.3.1. Market Size Estimation
2.3.1.1. Bottom-up Approach
2.3.1.2. Top-down Approach
2.3.1.3. Growth Forecast
2.3.2. Market Share Analysis
2.4. Assumptions for the Study
2.5. Limitations for the Study
3. Executive Summary
4. Market Insights
4.1. Market Overview
4.1.1. Drivers
4.1.1.1. High Prevalence of Infectious Diseases
4.1.1.2. Increasing Prevalence of Chronic Diseases
4.1.1.3. Growing Awareness Regarding Disease Diagnosis
4.1.3. Opportunity
4.1.3.1. Indonesia’s Rising Health Spending
4.1.3.2 Growing Scope for Foreign Investments
4.1.4. Challenges
4.1.4.1. Shortage of Healthcare Professionals
4.1.4.2. High Prices of Advanced IVD Products
4.2. Impact Assessment of COVID-19 Pandemic
5. Indonesia IVD Market, by Product
5.1. Introduction
5.2. Reagents, Assays, and Kits
5.3. Instruments/Analyzers
5.4. Software & Services
6. Indonesia IVD Market, by Technology
6.1. Introduction
6.2. Immunoassay
6.3. Clinical Chemistry
6.5. Hematology
6.6. Coagulation & Hemostasis
6.7. Electrolyte Analysis
6.8. Diabetes/Glucose Monitoring
6.9. Urinalysis
6.10. Other Technologies
7. Indonesia IVD Market, by Application
7.1. Introduction
7.2. Infectious Diseases
7.3 Oncology
7.4 Cardiology
7.5. Other Applications
8. Indonesia IVD Market, by End User
8.1. Introduction
8.2. Hospital Laboratories
8.3. Clinical Laboratories
8.3.1. large/Reference Laboratories
8.3.2. Medium-sized Laboratories
8.3.3 Small-sized Laboratories
8.4. Home Care/Self-testing
8.5. Other End Users
9. Distributor Profiles
9.1. MRK Diagnostics, PT.
9.2. PT. Diastika Biotekindo
9.3. PT. Diagnostika Sistem Indonesia
9.4. PT. Dexa Arfindo Pratama
9.5. PT. Sumbermitra Agungjaya
9.6. PT. Elo Karsa Utama
9.7. PT. Itama Ranoraya Tbk
9.8. PT. Cakra Medika Utama
9.9. PT. Karunia Jasindo
9.10. PT. Bavaria Combinindo
9.11. PT. Nelta Multi Gracia
9.12. PT. Bertiga Diagnostik Indonesia
9.13. PT. Inti Makmur Meditama
9.14. PT. ABADINUSA USAHASEMESTA
9.15. PT. Isotekindo Intertama
9.16. PT. Sciencewerke
9.17. PT. jaya health
9.18. PT. Hartech Indonesia
9.19. PT. DEMKA SAKTI
9.20. PT. UBC Medical Indonesia
9.21. PT. Pandu Biosains
10. Company Profiles
10.1. Abbott Laboratories
10.2. Agilent Technologies, Inc.
10.3. Becton, Dickinson and Company
10.4. Bio-Rad Laboratories, Inc.
10.5. Danaher Corporation
10.6. F. Hoffman-La Roche Ltd.
10.7. PerkinElmer, Inc.
10.8. Siemens Helathineers
10.9. Sysmex Corporation
10.10. Qiagen N.V.
10.11. Thermo Fisher Scientific Inc.
11. Appendix
11.1. Questionnaire
11.2. Available Customization
List of Figures
Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-side & Demand-side)
Figure 6 Market Size Estimation
Figure 7 Indonesia In Vitro Diagnostics Market, by Product, 2022 Vs. 2029 (USD Million)
Figure 8 Indonesia In Vitro Diagnostics Market, by Technology, 2022 Vs. 2029 (USD Million)
Figure 9 Indonesia In Vitro Diagnostics Market, by Application, 2022 Vs. 2029 (USD Million)
Figure 10 Indonesia In Vitro Diagnostics Market, by End User, 2022 Vs. 2029 (USD Million)
Figure 11 Market Dynamics
Figure 12 Tuberculosis Burden, By Country: Percentage of Global Tuberculosis Incidence (2020)
Figure 13 Indonesia: Estimated Number of New Cancer Cases (2020–2040)
Figure 14 Indonesia: Number of People with Diabetes (2021–2045)
Figure 15 Indonesia: Annual Healthcare Spending (2017–2022)
Figure 16 Indonesia: Medical Device and Equipment Imports (2019–2022)
Figure 17 Indonesia In Vitro Diagnostics Market Size, by Product, 2022 Vs. 2029 (USD Million)
Figure 18 Indonesia In Vitro Diagnostics Instruments Market Size, 2020–2029 (Hundred Units)
Figure 19 Indonesia: Percentage of Deaths Due to NCDs (% Of Total Deaths) (2010–2019)
Figure 20 Indonesia: Medical Device Imports (USD Million) (2019–2022)
Figure 21 Indonesia In Vitro Diagnostics Market Size, by Technology 2022 Vs. 2029 (USD Million)
Figure 22 Indonesia: Increase in Disease Prevalence Between 2009–2019 (%)
Figure 23 Indonesia: Hemophilia Prevalence (2014–2020)
Figure 24 Indonesia: Prevalence of Anemia in Pregnant Women Between 2014 And 2019 (%)
Figure 25 Indonesia: Diabetes Prevalence (2011-2030) (Million)
Figure 26 Indonesia In Vitro Diagnostics Market Size, by Application, 2022 Vs. 2029 (USD Million)
Figure 27 Indonesia: Diabetes Prevalence (2011–2045)
Figure 28 Indonesia: Estimated Number of New Cancer Cases (2020–2040)
Figure 29 Indonesia In Vitro Diagnostics Market Size, by End User 2022 Vs. 2029 (USD Million)
Figure 30 Indonesia IVD Market: Competitive Benchmarking
Figure 31 Abbott Laboratories: Financial Overview (2021)
Figure 32 Agilent Technologies, Inc.: Financial Overview (2021)
Figure 33 Becton, Dickinson and Company: Financial Overview (2021)
Figure 34 Bio-Rad Laboratories, Inc.: Financial Overview (2021)
Figure 35 Danaher Corporation: Financial Overview (2021)
Figure 36 F. Hoffman-La Roche Ltd.: Financial Overview (2021)
Figure 37 PerkinElmer, Inc.: Financial Overview (2021)
Figure 38 Siemens Healthineers AG: Financial Overview (2021)
Figure 39 Sysmex Corporation: Financial Overview (2021)
Figure 40 Qiagen N.V.: Financial Overview, (2021)
Figure 41 Thermo Fisher Scientific Inc.: Financial Overview (2021)
List of Tables
Table 1 Indonesia IVD Market: Impact Analysis of Market Drivers (2022–2029)
Table 2 Indonesia: Tuberculosis Statistics
Table 3 Indonesia: HIV Statistics (2021)
Table 4 Indonesia: Estimated Number of New Cancer Cases, by Type
Table 5 Indonesia: Diabetes Statistics (2021)
Table 6 Indonesia: Deaths Due to Cardiovascular Diseases (2020)
Table 7 Indonesia: Average Cost of Tuberculosis Testing
Table 8 Indonesia: COVID-19 Statistics: (As of 3rd August 2022)
Table 9 Indonesia In Vitro Diagnostics Market Size, by Product, 2020–2029 (USD Million)
Table 10 Indonesia In Vitro Diagnostics Market Size, by Technology, 2020–2029 (USD Million)
Table 11 Indonesia In Vitro Diagnostics Market Size, by Application, 2020–2029 (USD Million)
Table 12 Indonesia: Diabetes Statistics (2021)
Table 13 Indonesia: Estimated Number of New Cancer Cases, by Type
Table 14 Indonesia: Deaths Due to Cardiovascular Diseases (2020)
Table 15 Indonesia In Vitro Diagnostics Market Size, by End User, 2020–2029 (USD Million)
Table 16 Indonesia In Vitro Diagnostics Market Size for Clinical Laboratories, by Type (USD Million)
Table 17 List of Key IVD Products Distributors in Indonesia
Author Name:
Proudly Partnering With Enterprises Around the Globe
Quick Contact
Related Reports
IVD Assay Development Market - Global Opportunity Analysis and Industry Forecast (2024-2031)
Published Date: Oct-2024
Europe IVD Market - Opportunity Analysis and Industry Forecast (2024-2030)
Published Date: Jul-2024
Africa IVD Market - Opportunity Analysis and Industry Forecast (2024-2031)
Published Date: Jul-2024
IVD Reagents Market - Global Opportunity Analysis and Industry Forecast (2024-2031)
Published Date: Jul-2024
IVD Quality Control Market - Global Opportunity Analysis and Industry Forecast (2024-2031)
Published Date: Jan-2024
